Adaptimmune Therapeutics PLC
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $13.70M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | $1.20M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $40.90M | $-0.01 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | $128.20M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | $5.70M | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | Before market open | $200.00K | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 8, 2023 | Before market open | $7.30M | $-0.03 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 9, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 12, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 6, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 8, 2022 | Before market open | – | – | – |
Company guidance
Outlook given with results on May 13, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Tecelra sales | 2025 | $35.00M to $45.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Adaptimmune Therapeutics filed with the SEC
Adaptimmune Announces Delisting from Nasdaq
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Announces Entry into Definitive
Material agreement · Exit or restructuring costs · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Announces Changes to its Executive Leadership Team Based in the UK
Executive or director change · Other events · EX-99.1 to Form 8-K
Adaptimmune Reports Q3 2024 Financial and Business Updates
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial
Other events · EX-99.1 to Form 8-K
Adaptimmune Reports Q2 2024 Financial and Business Updates
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Receives U.S. FDA Accelerated Approval
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Adaptimmune and Galapagos sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Q1 2024 Financial and Business Updates
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Third Quarter Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Adaptimmune Reports Positive Data with Lete-cel 1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Second Quarter Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports First Quarter Financial Results and Business Update
Results of operations · EX-99.1 to Form 8-K
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Agreement terminated · Results of operations · Executive or director change · EX-99.1 to Form 8-K
and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
C reating a preeminent cell therapy company Leading T he C ancer R evoluti on
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
COOKIE COMMS SCRIPT FOR WEBCAST
Material agreement · Regulation FD disclosure · EX-99.3 to Form 8-K
Adaptimmune Announces Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K